Previous 10 | Next 10 |
The following slide deck was published by Aziyo Biologics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Aziyo Biologics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Aziyo Biologics press release ( NASDAQ: AZYO ): Q2 GAAP EPS of $0.69 beats by $1.25 . Revenue of $12.6M (+3.6% Y/Y) beats by $1.02M . Aziyo confirmed its expectation that total net sales for the full year 2022 will be in the range of $47 million to $50 mill...
SILVER SPRING, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today provided a business update and reported financial results for the second quarter June 30, 2022. Recent Highlights Total net sal...
Aziyo Biologics ( NASDAQ: AZYO ) entered into a $25M credit facility from SWK. The new credit facility provides for an initial term loan of $21M that the company plans to use to fund its ongoing commercial and product development initiatives, refinance its existi...
SILVER SPRING, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (the “Company”), a commercial-stage regenerative medicine company announced today that it has entered into a $25 million credit facility from SWK Holdings Corporation. The new credit...
Aziyo Biologics ( NASDAQ: AZYO ) announced that Aziyo co-founder C. Randal Mills, Ph.D. has assumed the President and CEO role on an on-going basis. Dr. Mills, who is internationally recognized for his contributions to the field of regenerative medicine, has served as the ...
SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis....
SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will...
Gainers: Seres Therapeutics (MCRB) +8%. Sana Biotechnology (SANA) +5%. Aziyo Biologics (AZYO) +4%. eXp World Holdings (EXPI) +4%. Aurora Innovation (AUR) +3%. Losers: Trip.com Group (TCOM) -9%. Xenon Pharmaceuticals (XENE) -8%. Accolade (ACCD) -6%. Ikena Oncology (IKNA) -6%. Cerus (...
Medicine company Aziyo Biologics' (NASDAQ:AZYO) co-founder, C. Randal (Randy) Mills, is appointed interim president and CEO. Mills succeeds Ronald Lloyd, who will remain with the company through Q3-end. Additionally, Co-founder Kevin Rakin is appointed executive chairman. ...
News, Short Squeeze, Breakout and More Instantly...
Aziyo Biologics Inc. Company Name:
AZYO Stock Symbol:
NASDAQ Market:
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding ref...
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”...
Negotiating multiple LOIs to divest Orthopedic business CanGaroo ® RM 510(k) resubmission to the FDA remains on track SimpliDerm ® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular ...